Skip to main content

Table 1 Patient characteristics and treatment effect of rivastigmine.

From: A pilot study of rivastigmine in the treatment of delirium after stroke: A safe alternative

Patient (gender) Age (years) IQCODE Stroke localization Stroke type NIHSS Highest daily dose (mg) Effect Delirium duration (days)
1(F) 69.2 53 Right PACI 5 6 Yes 4
2(M) 73.9 48 Right TACI 15 9 Yes 6
3(M) 85.0 70 Right POCI 3 3 Yes 3
4(M) 83.4 48 Right POCI 6 9 Yes 11
5(M) 80.7 48 Right PACI 4 6 Yes 3
6(F) 74.1 48 Right PACI 3 3 Yes 2
7(M) 53.4 48 Left PACI 16 12 Yes 14
8(M) 75.0 48 Right TACI 11 12 Yes 17
9(M) 82.5 48 Right POCI 4 3 Yes 2
10(F) 78.2 48 Right PACI 2 9 Yes 11
11(M) 85.5 58 Right LACI 3 3 Yes 2
12(M) 72.9 51 Left TACI 20 6 Yes 5
13(F) 72.8 78 Left ICH 9 9 No 14
14(M) 86.5 48 Left LACI 7 9 Yes 8
15(F) 79.3 48 Left PACI 9 6 Yes 4
16(M) 76.6 48 Left ICH 15 6 Yes 8
17(F) 79.4 48 Left ICH 9 9 Yes 7
  1. F = Female; M = Male. PACI = Partial Anterior Circulation Infarction; TACI = Total Anterior Circulation Infarction; POCI = Posterior Circulation Infarction; LACI = Lacunar Infarction; ICH = Intracerebral Hemorrhage